Illumina, Inc. ILMN
270.00
(3.90)
(1.42%)
as of 25 Sep
- Market cap
- $41.3B
- P/E
- 50.4×
Follow ILMN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Illumina, Inc. (ILMN) Return on equity
Illumina, Inc.'s return on equity over the twelve months to 30 June 2026 was 32.4%, down 1.0 percentage points from fiscal 2025 (33.4%). Over the past ten years it has ranged from −50.8% (fiscal 2022) to 33.4% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of −2.92% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 33.4% | 63.49 |
| FY2024 | −30.1% | (11.32) |
| FY2023 | −18.8% | 31.99 |
| FY2022 | −50.8% | (60.67) |
| FY2021 | 9.87% | (4.23) |
| FY2020 | 14.1% | (9.59) |
| FY2019 | 23.7% | (1.36) |
| FY2018 | 25.1% | (3.88) |
| FY2017 | 28.9% | 6.45 |
| FY2016 | 22.5% | (5.42) |
Against its own ten years
Low −50.8%
High 33.4%
Ten-year median
22.5%
Current reading's percentile
100
Return on equity against peers
| Company | Return on equity |
|---|---|
| GH Guardant Health, Inc. compare | 171.6% |
| IDXX IDEXX Laboratories, Inc. compare | 74.2% |
| ILMN Illumina, Inc. | 32.4% |
| IQV IQVIA Holdings Inc. compare | 22.8% |
| A Agilent Technologies, Inc. compare | 21.0% |
| DGX Quest Diagnostics Incorporated compare | 14.0% |
| WAT Waters Corporation compare | 1.92% |
| NTRA Natera, Inc. compare | −12.5% |
| MTD Mettler-Toledo International, Inc. compare | −736.4% |
| Diagnostics & Research industry median | −2.92% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ILMN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement